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Sllnlnlst  ry 
While recent evidence strongly suggests that the third complementarity determining regions 
(CDR3s)  of T  cell  receptors  (TCRs)  directly contact  antigenic peptides bound  to  major 
histocompatibility complex (MHC) molecules, the nature of other TCR contact(s) is less clear. 
Here we probe the extent to which different antigens can affect this interaction by comparing 
the responses of T cells bearing structurally related TCRs to cytochrome  c peptides and staphylococcal 
enterotoxin A (SEA) presented by 13 mutant antigen-presenting cell (APC) lines. Each APC 
expresses a class II MHC molecule (I-E  k) with a single substitution of an amino acid residue 
predicted to be located on the MHC c~ helices and to point "up" towards the TCR. We find 
that very limited changes (even a single amino acid) in either a CDR3 loop of the TCR or 
in a contact residue of the antigenic peptide can have a profound effect on relatively  distant 
TCR/MHC interactions. The extent of these effects can be as great as that observed between 
T  cells bearing entirely different TCRs and recognizing different peptides. We also find that 
superantigen presentation entails a distinct mode of TCR/MHC interaction compared with peptide 
presentation. These data suggest that TCR/MHC contacts can be made in a variety of ways 
between the same TCR and MHC, with the final configuration apparently dominated by the 
antigen. These observations suggest a molecular basis for recent reports in which either peptide 
analogues or superantigens trigger distinct pathways  of T  cell activation. 
l~ 
cent observations suggest that the TCR has a range of 
signaling capabilities.  Limited variations in peptide 
ligands can induce qualitatively different T cell responses (1-3), 
and simple competition between peptides binding to MHC 
or between TCK and peptide/MHC complexes cannot ade- 
quately explain the results.  In addition, it has been shown 
that T cell activation by a superantigen, in contrast to a pep- 
tide antigen, can occur without phosphoinositol turnover 
(4-6). 
One explanation for such differences in T  cell signaling 
is that the effect of alteration of CDR3/peptide interaction 
is not only confined to the immediate vicinity of interaction 
but instead can have more widespread effects on the overall 
MHC/TCR interaction. Consequently, the configuration of 
TCR/Ag/MHC complexes formed with structurally similar 
peptide antigens or with a superantigen could be different 
enough to variably influence the association of the engaged 
TCR with other cell surface molecules (CD3, CD4, or CD8, 
etc.),  thereby affecting  the outcome of signaling. 
To begin to address this question, we have developed an 
experimental system to evaluate the extent to which antigenic 
ligands affect the overall TCR/MHC  interaction. This is 
achieved by analyzing responses of T cells expressing struc- 
turally related TCKs to either peptide analogues or a bac- 
terial  superantigen, Staphylococcal  enterotoxin A  (SEA), 1 
presented by  mutant  I-E k molecules  that  contain  single 
amino acid substitutions of residues predicted to point "up" 
from the ol-helical regions of the MHC (7). The T cells are 
in most cases hybridomas derived from transgenic mice (8) 
expressing either the TCK c~ or fl chain of the T cell clone 
5C.C7 (9). They react to moth cytochrome c (MCC 88-103) 
peptide or its analogues bound to the class II MHC mole- 
cule, I-E  k. A subset of these hybridomas are able to recog- 
nize both wild-type MCC peptide (MCC [99K])  and the 
99E analogue containing a glu --~ lys substitution at residue 
99,  a position predicted to point up towards the TCK (8, 
10, 11). Others recognize the same cytochrome c peptide with 
1 Abbreviations  used in thispaper:  MCC, moth cytochrome c; SEA, staph- 
ylococcal enterotoxin A. 
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chain CDR3 region. As shown previously (8),  the CDR3 
region of the TCR directly contacts the antigenic peptide 
bound to MHC molecules. Analysis of both sets of hybrid- 
omas allows us to evaluate the effect of small defined changes 
in either TCR CDR3 or peptide on the overall MHC/TCR 
interaction. For comparison, we analyzed other cytochrome 
c-reactive hybridomas that express TCRs differing with re- 
spect to Vc~ allele or V~/gene segment, as well as T  cells 
with unrelated TCRs  that recognize peptides  other  than 
MCC. 
In this report, we show that T cells with TCRs differing 
only in a single CDR3 region of either the oe or ~  chain 
respond differently to peptide presented by the mutant APCs. 
T cell hybridomas that are crossreactive to two related pep- 
tides  also  show  strikingly different  sensitivities  to  some 
I-E~  k and bEa  k mutants,  depending on which peptide is 
being  recognized.  Surprisingly,  the  extent  of TCR/pep- 
tide/MHC changes brought about by small changes in an 
apparent CDR3/peptide contact can be as great as those ob- 
served between T cells expressing unrelated TCRs. Both these 
results suggest that the TCR/peptide interaction dominates 
the final configuration of the ternary complex. In the case 
of the same  T  cell responding to  superantigen/I-E  k vs.  a 
peptide/I-E  k complex, the sensitivities to the I-E  k mutations 
are also very different. Taken together the data suggest that 
TCR/MHC interactions are extremely "fluid" and can be 
influenced profoundly by small changes in the antigen. As 
this may influence signaling through the TCR, it has impor- 
tant implications for our understanding of thymic differenti- 
ation and peripheral T  cell tolerance. 
Materials and Methods 
Mutant APC Lines.  Full-length I-E  k o~ and ~ chain cDNAs 
(12) cloned in the Bluescript SK- plasmid (Stratagene, San Diego, 
CA) (13) were subjected to site-directed mutagenesis (14). Oligo- 
nucleotides for mutagenesis were synthesized with a DNA syn- 
thesizer (394; Applied Biosystems,  Inc., Foster City, CA). Mutant 
plasmids were identified  by DNA sequencing  (Sequenase sequencing 
kit) (United States Biologics,  Indianapolis,  IN). The eukaryotic  ex- 
pression vectors pBJ1-Neo and PBJ1 were used to express the cr 
and/3 chain, respectively (15). 
The cr  heterodimer was reconstituted by expression of a mu- 
tant c~ or/3 chain with the complementary wild-type chain by 
cotransfection in Chinese hamster ovary (CHO) cells as described 
by Wettstein et al. (13). G418 (Gibco Laboratories, Grand Island, 
NY) -resistant cells were pooled and sorted after staining with anti 
I-E mAb 17.3.3 (16). Positive  cells were cloned by cell sorting. The 
levels of surface expression of each mutant and wild-type I-E  k are 
within a twofold range. 
Peptides and Staphylococcal Toxins.  Peptides  used in the Y cell 
activation  assays are  as  follows: hemoglobin  ~dmin 64-76, 
GICKVITAFNEGLK (the  gift of Dr.  Paul Allen,  Washington 
University, St.  Louis, MO);  and ~, repressor P12-26, LEDAR- 
RLKAIYEKICK  (the gift of  Dr. Malcolm L. Gefter, Massachusetts 
Institute  of Technology). Biotinylated hemoglobin/3  amin 53-76, 
biotin-AIMGNPKVKAHGKKVITAFNEGLK,  MCC  88-103 
(MCC[99K]), ANERADLIAYLKQATK, biotinylated MCC 82- 
103, biotin-FAGIICKANERADLIAYLKQATK,  substituted MCC 
88-103 peptides MCC(99E) (glutamine substituted at position 99), 
peptide MCC (102E) (glutamine substitute at position 102), and 
MCC(102K) (lysine substituted at position 102) and biotinylated 
MCC(99E) 82-103 were synthesized by the Stanford Peptide and 
Nucleic Acid Analytical facility using standard fmoc chemistry on 
a synthesizer (9050; Milligen, Burlington,  MA). SEA was pur- 
chased from Toxin Technologies (Sarasota, FL). 
T Cell Hybridomas.  The T cell hybridoma 3I was derived from 
an A/J mouse immunized with X repressor ci P 1-102 (17). Y01.6 
is from CE/j (Hb~') mice immunized with CBA/J (HbB  d) Hb 
(18), and 2B4 is from a B10.A mouse immunized with pigeon 
cytochrome c (19). Hybridomas 104, 226, 115, K5, K17, K20, E6, 
E20, E22, E26, and E28 were obtained by immunizing mice ex- 
pressing the transgene for either the TCR c~ or ~ chain of the 
cytochrome c-reactive T cell clone 5C.C7 (8). The primary TCR 
structure of these hybridomas is presented in Table 1. 
Antigen Presentation Assays.  Antigen presentation assays were 
carried out with 2  x  104 APCs, 5  x  104 responder cells (T cell 
hybridomas), and various concentrations of SEA or peptide in a 
final volume of 0.2 ml, and incubated for 18 h at 37~ 
The amount of Ib2 produced at each antigen concentration was 
assayed in duplicate using the IL-2-dependent  HT-2 cell line (20). 
A complete dose-response titration was performed independently 
at least twice and in many instances more than three times to verify 
reproducibility. Presentation efficiency  was estimated as follows: 
the  antigen  concentration  required to  elicit half-maximal Ib2 
production by the wild-type APC was defined as C1/zw,, and that 
of a mutant APC to elicit the same amount of Ib2 was defined 
as Cl/~ut. The effect of the mutant I-E  k lines on presentation was 
evaluated by taking the ratio of C1/2mu, to C~/zw,. Values reported 
in Fig. 5 represent an average from two to three independent ex- 
periments. 
Binding  Assays.  FACS  |  analysis (Becton Dickinson &  Co., 
Mountain View, CA) of peptide and SEA binding to I-E  k CHO 
cells was carried out with biotinylated MCC 99K and 99E pep- 
tides and hemoglobin peptide using a modification of the protocol 
of Busch et al. (21), and biotinylated SEA using a modification 
of the protocol of Herman et al. (22). Binding was carried out 
at 37~  for 4 h in PBS, 5% FCS, 0.1% sodium azide followed 
by incubation with allophycocyanin  (Biomeda, Foster City, CA) 
or PE (Southern Biotechnology Associates, Birmingham, AL) - 
conjugated streptavidin. To normalize peptide binding with cell 
surface I-E expression, cells  were simultaneously stained with anti- 
I-E  antibody  17.3.3 (16) followed by  FITC-conjugated  goat 
anti-mouse IgG (Sigma Chemical Co., St. Louis, MO). 
Results 
Expression of Mutant IF. k on CHO  Cells.  A series of six 
I-E~  k and seven I-E~' mutants were made by site-directed 
mutagenesis (14) and transfected into CHO ceils. Each mu- 
tant chain expresses a single substitution of an amino acid 
residue that is predicted to lie on "top" of the c~ helices that 
form the MHC/peptide binding groove (7). The one excep- 
tion is the mutation at position 72 of the MHC eel helix. 
The side chain of o~72 is predicted to point upwards and thus 
is potentially available to contact the TCR. The amino acid 
substitutions were selected to disrupt interactions between 
the TCR and MHC maximally while maintaining the na- 
tive tertiary structure of the I-E  k molecule. To preserve the 
structure, the substituted amino acids are similar in hydropho- 
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Hybidoma  Vo~  c~ V-J junction  Jc~  V/~  /3 V-D-J junction  J/~ 
2B4  11.2  CAALRVTGGNNKLTF  B4  3 
Y01.6  16 
3I  2  CAASAGTGSKLSF  TA1  1 
115  11,1  CAAEPSNTNKVVF  C7  3 
226  11.1  CAAEPSSGQKLVF  84  3 
104  11.2  CAAEPSSGQKLVF  84  3 
E6  11.1  CAAEASNTNKVVF  c7  1 
E28  11.1  CAAEASNTNKVVF  C7  1 
E20  11.1  CAAEASNTNKVVF  C7  1 
E22  11.1  CAAEASNTNKVVF  C7  6 
E26  11.1  CAAEASNTNKVVF  C7  6 
K5  11.1  CAAEASNTNKVVF  C7  14 
K17  11.1  CAAEASNTNKVVF  C7  14 
K20  11.1  CAAEASNTNKVVF  C7  14 
CASSLNWSQDTQYF  2.5 
CASSQEGGDYAEQFF  2.1 
CASSLNN ANSDYTF  1.2 
CASSLNN ANSDYTF  1.2 
CASSLNN ANSDYTF  1.2 
CASS N NSDYTF  1.2 
CASSQGQGVGSDYTF  1.2 
CASSQGQGRGTEVFF  1.1 
CASSNHLGRHNNQAPL  1.5 
CASSSWTGK  SAETLY  2.3 
CAWSPPSGQTEVFF  1.1 
CAWSPPEGQTEVFF  1.1 
CAWSQGRED TLYF  2.4 
vcy, c~v-J  junction, J~, v/3,/3V-D-J  junction, and J/3 sequences  are listed or indicated for TCKs of 2B4 (19), YO1.6 (Paul Allen, personal communi- 
cation), and 3I (44). 115, 226, and 104 express the TCR/3 chain of the 5C.C7 T cell line. E6, E28, E20, E22, E26, K5, K17, and K20 express 
the 5C.C7 TCR c= chain (8). 
bicity to the wild-type amino acid. To disrupt contacts with 
the TCIL,  the mutations either reverse charges (c=79,/359, 
/369,  and/384,  Glu to Lys) or increase the size of the side 
chain to promote steric hindrance (o~65, o~68, ol72, and/373, 
Ala to Val;/381, His to Tyr; c=57, Set to Asn; and/377, Thr 
to Gin) (Fig.  1). For c~61,/364,  the Gln residue is changed 
to Arg;  this not only increases  the side chain volume but 
also introduces  a basic guanido  group. 
Cell  surface expression  of I-E  k was verified by staining 
with anti-I-E mAbs, including 14.4.4 (16),  17.3.3 (16), Y17 
(23), 40B (24), 40D (24), and ISCR3 (25). All mutant and 
wild-type I-E  k transfectants stain within a twofold intensity 
range on FACS  |  analysis with all antibodies. The exceptions 
are: c~61, which does not stain with 14.4.4, and/369, which 
helix 
a57 S>N 
a61 O.>R ~"'-~~7  a65 A>V \ 
r  A>V 
~72 A>V 
=79 E>K 
A 
//Nx 
I}1  helix 
9 E>K 
~/~ ~  ~.~//~  p64 O>R 
A>V 
1~77 T>O. 
1381 H>Y 
1~84 E>K 
Figure  1.  I-E  k mutants. The position of the amino acid substitution 
of 13 I-E  k mutants. The location of the mutated residues is shown on 
an adaptation of the MHC class II model alignment of Brown et al. (7). 
has reduced 40D  staining  (more than  threefold)  (data not 
shown).  Because these two clones stain normally with the 
other anti-I-E  antibodies,  it is likely that  these two muta- 
tions,  o161 and/369,  lie within or near the determinant  of 
epitopes for 14.4.4 and 40D, respectively. The fact that  all 
the mutants retain the capacity to be recognized by five or 
more antibodies indicates that  their secondary and tertiary 
structure  is not grossly distorted. 
Antigen Binding of Mutant I-E  k on CHO Cells.  Since the 
transfectants were used as APCs, we assessed  the ability of 
each line to bind peptides and the superantigen,  SEA.  All 
mutant and wild-type I-Ek-expressing  cells bind biotinylated 
MCC(99K), MCC(99E), and biotinylated hemoglobin pep- 
tides to a similar extent (within a threefold range) (Fig.  2). 
These results are consistent with the prediction that the mu- 
tated amino acid residues point away from the MHC peptide 
groove (7) and therefore do not interfere with peptide binding. 
MCC(99K) and MCC(99E) bind to each mutant similarly, 
confirming prior observations that position 99 of the cyto- 
chrome c peptide does not affect MHC binding and thus is 
consistent with evidence that  position 99 directly contacts 
the TCR (8,  26). 
Biotinylated  SEA  binds  to  the  mutant  I-Ek-expressing 
CHO cells to a similar extent as wild-type I-Ek-expressing 
cells, with the exception of/369 and/381 (Fig. 3). With/381, 
there is no detectable SEA binding,  consistent with muta- 
genesis studies on HLA-DR, the human equivalent of I-E  k 
(27, 28)./369 showed decreased binding with fourfold less 
staining at the highest concentration of SEA used (40 gg/ml). 
Responses of Crossreactive Hybridomas to Different Antigens, 
Hybridomas 104 and 226 express an identical TCK/3 chain 
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Figure 2.  Peptide binding by mutant MHC molecules. Binding of biotinylated wild-type MCC(99K) and substituted MCC(99E) in a FACS  |  assay 
(see Materials  and Methods) by the mutant I-Ek transfectants,  wild-type I-Ek (Wild Type), and untransfected  CHO cells (CLIO) is shown. 
(derived from 5C.C7 TCR B chain transgenic mice). Their 
TCR o~ chains have identical V-J junctional regions but are 
associated with different VoL gene segments (Vcdl.1 for 226, 
Vottl.2 for 104). They recognize  both wild-type MCC pep- 
tide (99K) and the MCC(99E) variant (Lys to Glu substitu- 
tion at position 99), as well as the superantigen,  SEA. Sub- 
stitutions at this position  have no effect on MHC binding 
but appear to alter the interaction of the peptide with the 
TCR a  CDR3 region (8). 
As shown in Figs. 4 A and B, and 5, mutations at several 
positions affect the response to 226 and 104 to the MCC(99K) 
and MCC(99E) peptides differently. The response to MCC 
1001  --~--  CHO 
Biotinylated  SEA  Binding  =.m=.  Wild  Type 
=  ec57 
~q 
r  ~65 
~  o~68 
~  ~72 
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.....  A  1381 
1~  []  1384 
I  10  100 
Biotinylated  SEA  mg/ml 
Figure 3.  SEA binding by mutant MHCs. Shown are 
binding curves of the mutant I-Ek transfectants, wild-type 
I-E  k (Wild Type), and untransfected CHO cells (CLIO) 
shown with biotinyhted SEA in a FAC-.S  r  assay  as de~'ibed 
in Materials and Methods. 
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Figure  4.  Dose-response  curves of hybridomas  226,  104, E6, E20, and E28. IL-2 units vs. concentration of MCC(99K), MCC(99E), and SEA for 
wild-type I-E  k transfectant  and I-E~ B1 helix mutants is shown for 226 (V~xll.1/VB3)  (,4) and  104 (V~xll.2/VB3) (B). Titration of E16, E20,  and 
E28  (Vtx11.1/V~l) with MCC(102E)  is shown in C. IL-2 was measured by HT-2 assay as described  in Materials  and Methods. 
(99K) is enhanced by B81 but not significantly affected by 
the 869 mutation. With the 99E peptide, 869 eliminates the 
response and 881 reduces rather than enhances the response. 
In addition, c~65, c~68, 864, 873, and 877 all show different 
effects on the presentation of the 99E peptides compared with 
99K. Similar variability in the responses of hybridoma 104 
to 99K and 99E (Figs.  4 B  and 5) is also observed.  Thus, 
varying the antigenic peptide can significantly alter the in- 
teraction  of the same TCR with the I-E  ~ mutants. 
The response of 226 to SEA is inhibited only by the 869 
717  Ehrich et aL 
and f181 mutations,  the two mutations that inhibit  SEA 
binding. In addition, c~65 and 859 diminish the responses 
of 104 but not 226. The patterns of sensitivity to the mutant 
APCs are completely different than those observed for pep- 
tide presentation.  This indicates that SEA presentation  en- 
tails a distinct mode of MHC/TCR interaction. 
Responses ofT Cells with TCRs Differing Only in the CDR3 
Region of the c~ Chain.  Hybridomas 115 and 226 express an 
identical TCR. 8  chain (derived from 5C.C7 TCR B chain 
transgenic mice). Their o~ chains use the Vodl.1 gene seg- Hybridoma:  2Z6 
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Figure  5.  Efficiency  of antigen 
presentation by mutant APCs to T 
cell hybridomas.  The ef~ciency of 
antigen  presentation  of  the  six 
I-E,~  k and seven I-E~' mutant APCs 
is depicted schematically. Details of 
the methods used to calculate pre- 
sentation et~ciency, and descriptions 
of the T  cell hybridomas,  are in- 
cluded  in  the  Materials  and 
Methods.  Highest concentration  of 
peptide used: MCC(99K), 20/~m; 
MCC(99E), 100/~m; MCC(102E), 
200/~m;  MCC  (102I{),  100/~m; 
Hb, 20/~m; ~, rep, 80/~m; SEA 5, 
~g/ml. 
ment but have different CDR3 sequences. Responses to the 
MCC(99K) peptide presented by some of the mutant APCs 
differ markedly. While/364,  B69,  and/~77 fail to elicit re- 
sponses from 115, they show no (~69) or limited (/364, /377) 
effect on 226.  In addition,  an enhancement in the response 
of 226 to 99K peptide presented by/381 is not observed with 
115. These results show that differences in the CDR3 region 
of the ot chain also affect the interaction of the TCR with 
MHC (Fig.  5). 
Responses ofT Cells with TCRs Differing Only in the CDR3 
Region of  theft Chain.  Three hybridomas, E6, E20, and E28, 
specific for the MCC peptide variant MCC(102E)  (Thr -'* 
Glu substitution  at position 102) were analyzed. They ex- 
press the transgenic 5C.C7 TCR o~ chain (Vodl.1) together 
with VB1. E6 and E28 use JB1.2, whereas E20 expresses  JBI.1. 
Each hybridoma has a distinct TCR B junctional  sequence 
(Table 1). Ahhough these hybridomas respond to some mu- 
tant APCs similarly, they respond differently to others. Most 
strikingly, E28 alone shows an enhanced response with the 
/364 mutant,  whereas recognition  by the other two T  cell 
hybrids is dramatically impaired. Mutations at c~61, c~68, c~72, 
and ~81 also variably affect these three T  cells (Figs.  4 C 
and 5). These results indicate that amino acid residues within 
the B chain CDR3 can significantly affect the interaction of 
the TCR with the MHC molecule  as well. 
Another set of 102E-reactive T cell hybridomas, E22 and 
E26, were analyzed. Similar to E6, E20, and E28,  they are 
also derived from 5C.C7 o~ chain transgenic mice and express 
the 5C.C7 TCR o~ chain. Both express V~6 but with different 
junctional regions (Table 1). The responses of these two hy- 
bridomas to the panel of APCs show very similar patterns 
(Fig. 5): Mutations at B64,/369,  and/377  reduce the ability 
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mutations at other positions of I-E  k molecule have no mea- 
surable effect. 
Because the response patterns of E6, E20, and E28 to the 
mutant I-Ek's are quite distinct while those of E22 and E26 
are quite similar, an additional set of T cell hybridomas with 
TCRs differing only in the TCR fl CDR3 region were ana- 
lyzed. Hybridomas KS, K17, and K20 are also derived from 
5C.C7 TCR ol chain transgenic mice but use Vf114 and recog- 
nize the MCC(102K) peptide (Thr --~ Lys substitution at po- 
sition 102) (Table 1). K5 and K17 have nearly identical TCR 
sequences with the exception of a single amino acid lo- 
cated in the CDR3 region. In K17,  this amino acid (Glu) 
is predicted to contact the Lys at position 102 of the peptide 
(8).  At the corresponding position in K5, a serine residue 
is present. K20 also has a glutamic acid within the CDR3 
but expresses Jf12.4 instead of Jill.l,  as is the case with K5 
and K17.  Surprisingly, although the TCR structure of K5 
and K17 differs by a single amino acid, their responses to 
two mutants, fl59 and fl64, are strikingly different, fl59 and 
fl64 exert no effect on the presentation of 102K to K17 but 
severely (fl64) and moderately (fl59) inhibit the presentation 
to K5. In contrast to both K5 and K17, ol68 and c~72 show 
enhanced presentation with K20 while fl81  and fl84 have 
no effect on presentation to K20  (Fig.  5). 
Responses of T Cells with TCRs Differing Only in the Vcr 
Gene Segment (Vc~11.1 vs. Vcr11.2): Hybridomas 104 and 226. 
The difference between the TCRs expressed by hybridomas 
104 and 226 is limited to five amino acids in the Vc~ gene. 
Three nonconservative amino acid changes are located in the 
D  -~ E loop (close to CDR1).  The other two differences 
are adjacent to CDR1 on the TCR C strand (29). Comparing 
104 and 226 enables us to assess the effects of limited varia- 
tion in the Vc~ gene segment on the interaction of the TCR 
with the MHC/peptide complex. 
As  discussed previously,  three of the I-E  k fl  mutants 
show differing effects in presenting 99K peptide to these two 
hybridomas. Mutations at fl64 and fl69 abolish presentation 
to hybridoma 104, but have small or no effect on the responses 
of 226.  The response of 226, but not 104, is enhanced by 
the fl81  mutant. 
I-E  k mutants also affect the presentation of 99E peptide 
differently, fl73 and fl81 impair presentation to both hybrid- 
omas but to varying degrees. 226, but not 104,  shows en- 
hanced responses to the oe65 and o~68 mutations. 
Presentation of SEA to T Cells Expressing V,~11.1 vs. V~II.2 
Together with VB3: Hybridomas 115, 2B4, 104, and 226.  The 
2B4 hybridoma uses Vot11.2  and Vfl3 with junctional se- 
quences differing from 115 in both the c~ and fl CDR3s, in 
addition to the Vol gene segment (115 uses V,~11.1). As ex- 
pected, fl69 and fl81, which show reduced binding to SEA, 
fail to elicit responses from any of these hybridomas. Interest- 
ingly, 2B4 (V,~11.2) but not 115 (V,~11.1) shows reduced re- 
sponses with c~68 and fl59. In an analogous fashion, responses 
of 104 (V,~11.2) but not 226 (V,~11.1) are diminished by c~68 
and fl59 (Figs.  4, A  and B,  and 5). 
It has been shown that superantigen recognition does not 
depend on MHC class II amino acid residues located inside 
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the peptide binding groove (30). These results expand on their 
finding and establish that MHC/TCR interactions are also 
dissimilar in the T cell recognition of a superantigen/MHC 
complex compared with a peptide/MHC  complex. 
Presentation of Peptide Antigens to  T  Cells with Unrelated 
TCRs.  The activation of three hybridomas expressing struc- 
turally unrelated TCRs by these panels of mutant APCs was 
also compared. The three are 2B4 (19), which recognizes moth 
or  pigeon  cytochrome c  and  expresses  V~11.2  and  Va3; 
Y01.6  (18),  which recognizes a hemoglobin flami, peptide 
and expresses Va15;  and 3I, which recognizes a X repressor 
peptide and expresses V~2 with Val (31). Results are sum- 
marized in Fig.  5. Some mutants have no effect on peptide 
presentation while others abolish stimulation entirely. There 
is considerable variation among some of the mutants in their 
capacities to stimulate these T cells. This finding is consis- 
tent with prior reports (30, 32) probing TCR/MHC inter- 
action with T ceils of structurally unrelated or uncharacter- 
ized TCRs. It is interesting that the extent of these differences 
is no greater than that found between hybridomas with much 
more similar TCRs  and antigens discussed previously. 
Discussion 
In this report, we find that single amino acid substitutions 
of the antigenic peptide, or changes in a single CDR3 re- 
gion, can dramatically change the overall TCR/MHC inter- 
action.  It is also clear that superantigen/MHC complexes 
have a completely different mode of interaction with TCR 
compared with peptide/MHC ligands. These results suggest 
contacts between the TCR and MHC are extremely "fluid" 
in that they can be made in a variety of ways with the final 
configuration of TCR/Ag/MHC largdy determined by the 
antigen. This conclusion is deduced from three lines of evi- 
dence. (a) In the case of peptide/MHC ligands, TCRs that 
are crossreactive to different peptide analogues show very 
different sensitivities to both I-Ek~ and the I-Ek~ mutants 
(o~65, c~68, fl64, fl69, fl73, fl77, B81), depending on the pep- 
tide being recognized (Figs. 4 and 5); thus, the same TCR 
can contact the same MHC in more than one way. (b) Very 
limited differences in either the TCR oe or fl CDR3, which 
contact the peptide, can alter TCR/MHC  interactions on 
a very broad scale (cr  fl68, ol72, fl59, fl64, fl81, fl84), in- 
dicating that a change in CDR3/peptide interaction alters 
what must be very distant TCR/MHC contacts (see discus- 
sion below). This again suggests flexibility in TCR/MHC 
interaction and the dominant effect of antigen. (c) The use 
of a particular Vc~ or Vfl gene segment does not seem to 
predispose the TCR towards contacting the MHC in any 
particular way (Fig.  5). 
It is striking that the extent of the effects on MHC/TCR 
interaction accompanying a changed CDR3/peptide  inter- 
action can be as great as those observed with T  calls using 
TCRs with different Vfl gene segments or with unrelated 
TCRs recognizing different peptide antigens. It was unex- 
pected that T ceils that express different Vc~ gene suballeles 
(104 and 226) would also show similar degrees of variation 
in their sensitivity to the mutant MHCs. This finding is es- pecially remarkable as none of the sequence differences be- 
tween Vo~11.1 and Vot11.2 are nonconservative amino acid 
changes located in the CDR1 or CDR2 loops, which puta- 
tively contact the MHC ol helices (33-36). It should be noted, 
however, that the five amino acids that distinguish  Vc~11.1 
from Vc~11.2 are located on the D -* E loop and the C strand. 
Our recent mutagenesis study of the 2B4 TCR has demon- 
strated that single nonconservative amino acid substitutions 
in the C strand of the o~ chain can dramatically affect recog- 
nition of MCC (Rock et al., manuscript in preparation). 
Moreover, a computer modeling study suggests that substi- 
tutions in the D -* E loop could influence the conformation 
of the adjacent TCR ol chain CDR1. 
It is unlikely that the results cited in point (a) above are 
due to an interruption of direct contacts between the TCR 
CDR3 loops and the MHC ct helices. Given the predicted 
distance between these mutated amino acid residues on the 
I-E  k molecule (~o25 A  between the ot carbon  of residues 
B59 and/~81), it is inconceivable that they could be simul- 
taneously contacted by the altered amino acids of a single 
CDR3 loop. 
It is also unlikely that our observations merely reflect the 
relative sensitivity of these T cells to Ag/MHC stimulation. 
Although there is a correlation  between C1/2wt and sensi- 
tivity to the mutant APCs for SEA recognition, no consis- 
tent correlation can be discerned in peptide recognition. For 
example, while the greater  C1/2wt of 99E for 104  to 226 
correlates with more pronounced effects  by the mutant I-Ek's 
on 104 than 226, no such correlation can be found for 226, 
104, and 115 responding to the 99K peptide; K5, K17, and 
K20 responding to 102K peptide;  or E6, E20, and E28 re- 
sponding to 102E peptide. Last, it is unlikely that our obser- 
vation derived from uncontrolled variables in the experiments. 
We have tested two independent clones derived from the same 
fusion that have the same TCR and found them to yield iden- 
tical  patterns  with  the  panel  of I-E  k mutants  (data  not 
shown). 
Our results suggest there is no a priori mode of interac- 
tion between the TCR and the MHC, but rather an "op- 
timization" of the contacts is obtained for each ternary com- 
plex.  Superantigen  interaction  with  TCR  and  MHC  as 
compared with peptide antigen may represent the most ex- 
treme case  of such optimization. In this context it is interesting 
to note the recent report that a CDR3 loop of an Ig heavy 
chain can change markedly in both main and side chain con- 
formations to enable high affinity antigen recognition (37). 
In the case of TCR, both ct and fl chain CDR3s are as long 
as Ig heavy chain CDR3s and several residues longer than 
light chain CDR3s. The enhanced conformational flexibility 
of TCR CDR3 loops relative to those of antibodies could 
lead to significant secondary effects on the structure of  juxta- 
posed CDR1 and CDR2 loops. In addition,  the binding of 
TCR to peptide/MHC complexes could also involve water 
acting as an "adaptor" molecule, as has been proposed  for 
antigen/antibody interactions (38). By filling gaps between 
loops on the TCR and between the TCR and antigen/MHC 
complex, water molecules could therefore be involved directly 
in the interaction of TCR and antigen/MHC and stabiliza- 
tion of different conformations of the TCR/Ag/MHC com- 
plex. Thus, broad-scale induced fit of ligand-binding surfaces 
on TCR ct and B chains might be a general component of 
recognition by the TCR. 
A  consequence of this broad-scale "induced fit" model 
would be that structurally related ternary complexes could 
differ in conformation of TCR and/or Ag/MHC. Along this 
line, an antibody-induced conformational change of TCR has 
been postulated by Rojo and Janeway (39) to explain the differ- 
ences in T cell activation potency between different anti-TCR 
antibodies. Small conformational changes in an MHC class 
I molecule have also been found to be induced by binding 
different peptides (40). Structurally related ternary complexes 
may also differ in the "angle of approach" between the TCR 
and the Ag/MHC complex and/or a different intermolecular 
orientation, as is suggested by the observation that some T 
cells  are  sensitive to  mutations  located  in  the  E~  chain 
whereas others are not. 
As T cell signal transduction through the TCR requires 
the association of TCR, CD3 molecules (% ~, e, ~', ~/), and 
either CD4 or CD8, as well as other cell surface accessory 
molecules (41, 42), one could envision that differences in the 
configuration of TCR/Ag/MHC may have qualitative and/or 
quantitative effects on the subsequent association of the en- 
gaged TCR with other T cell surface molecules. This may 
be analogous to growth factor receptors, where dimerization 
and conformational changes induced by ligand binding ap- 
pear to be important in signaling  (43). 
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